

CHAPTER ONE: INTRODUCTION.....	1
STUDY GOALS AND OBJECTIVES.....	1
REASONS FOR DOING THE STUDY	1
SCOPE OF REPORT	2
INTENDED AUDIENCE.....	2
METHODOLOGY	3
RELATED BCC STUDIES	3
ANALYST CREDENTIALS.....	3
BCC ONLINE SERVICES.....	3
BCC ONLINE SERVICES.....	4
DISCLAIMER	4
 CHAPTER TWO: SUMMARY.....	 5
CANCER PROFILING AND PATHWAYS	5
CANCER PROFILING AND PATHWAYS (CONTINUED).....	6
<i>SUMMARY TABLE MARKET FOR CANCER PROFILING</i>	
<i>TECHNOLOGIES, THROUGH 2015 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE MARKET FOR CANCER PROFILING</i>	
<i>TECHNOLOGIES, 2009–2015 (\$ MILLIONS)</i>	7
 CHAPTER THREE: OVERVIEW	 8
INTRODUCTION	8
INTRODUCTION (CONTINUED)	9
INTRODUCTION (CONTINUED)	10
LINKING CANCER DISEASE THROUGH PATHWAY PROFILING	11
HISTORICAL FACTS	11
Historical Facts (Continued)	12
Historical Facts (Continued)	13
Historical Facts (Continued)	14
Historical Facts (Continued)	15
CLINICAL UTILITY OF MOLECULAR PROFILING	16
Clinical Utility of ... (Continued)	17
CLINICAL PROFILING, FUTURE GOALS.....	18
MOLECULAR PROFILING APPROACHES.....	19
<i>TABLE 1 DIFFERENT TOOLS FOR MOLECULAR PROFILING OF</i>	
<i>CANCER</i>	19
Molecular Profiling Approaches (Continued)	20
 CHAPTER FOUR: CURRENT PROFILING TECHNIQUES	 21
GENOMIC PROFILING.....	21
<i>TABLE 2 LIST OF TECHNIQUES/TOOLS FOR GENOMIC PROFILING</i>	22
GENOMIC PROFILING (CONTINUED)	23
<i>TABLE 3 GENOMIC REVENUE AND FORECAST, THROUGH 2015 (\$</i>	
<i>MILLIONS)</i>	24

<i>FIGURE 1 GENOMIC REVENUE AND FORECAST, 2009–2015 (\$</i>	
<i>MILLIONS)</i>	24
GENOMIC PROFILING (CONTINUED)	25
MICROARRAYS.....	26
<i>TABLE 4 COMMONLY USED DNA MICROARRAYS</i>	27
Oligonucleotide Microarrays	27
Spotted Microarrays	28
Spotted Microarrays (Continued).....	29
Microarrays and Applications	30
COMPARATIVE GENOMIC HYBRIDIZATION (CGH).....	31
Comparative Genomic Hybridization (Continued).....	32
Array Comparative Genome Hybridization.....	33
Array ... (Continued)	34
Applications of Array-CGH	35
CGH and Cancer.....	35
Array CGH and Neuroblastoma.....	35
Key Companies	36
<i>TABLE 5 SELECTED COMPANIES WITH MICROARRAY</i>	
<i>TECHNOLOGIES</i>	37
Company Descriptions.....	37
Arrayit Corp.	37
PerkinElmer.....	38
Invitrogen	39
Agilent	39
Roche	40
SINGLE NUCLEOTIDE POLYMORPHISM (SNP).....	41
MULTI-COLOR FISH.....	42
SPECTRAL KARYOTYPING	42
Company	43
iKaryos Diagnostics,	43
DNA SEQUENCING.....	43
Emerging DNA sequencing Technologies.....	44
Fluorescent <i>in situ</i> Sequencing (FISSEQ)	44
Pyrosequencing	45
Massively Parallel Signature Sequencing (MPSS).....	45
Single-Molecule Sequencing.....	45
Bacterial Artificial Chromosome (BAC)-end	
Sequencing.....	46
In vitro Clonal Amplification	46
Parallelized Sequencing	47
Sequencing by Ligation	47
Microfluidic Sanger Sequencing	47
Other sequencing technologies.....	47
Applications to Cancer	48

Sequencing Technologies, Market, and Their Applications.....	49
<i>TABLE 6 COMPANIES WITH SEQUENCING TECHNOLOGIES</i>	50
Key Companies	50
Key Companies (Continued).....	51
The Next Next-Generation Companies	52
Company Descriptions.....	53
Illumina.....	53
Illumina (Continued)	54
Illumina Products	55
Complete Genomics	56
Complete ... (Continued).....	57
454 Life Sciences.....	58
Applied Biosystems.....	59
Applied ... (Continued).....	60
Patents and Sequencing	61
<i>TABLE 7 SEQUENCING PATENTS AWARDED</i>	62
Genomics and Cancer—Some Examples	63
<i>TABLE 8 MUTATIONS IDENTIFIED IN CANCER</i>	64
<i>TABLE 8 (CONTINUED)</i>	65
Mutations Predicting Resistance to Targeted Therapies	65
TRANSCRIPTOMIC PROFILING	66
<i>TABLE 9 TRANSCRIPTOMIC TECHNIQUES</i>	67
MICROARRAY-BASED GENE EXPRESSION PROFILING	67
MICROARRAY-BASED GENE ... (CONTINUED)	68
SERIAL ANALYSIS OF GENE EXPRESSION (SAGE)	69
MRNA	70
DATA ANALYSIS AND DESIGN	70
Data Analysis and ... (Continued)	71
Data Analysis and ... (Continued)	72
TILING ARRAYS	73
QRT-PCR	73
APPLICATIONS TO CANCER.....	73
Applications ... (Continued).....	74
FUTURE.....	75
EPIGENOMIC PROFILING	75
OVERVIEW AND INTRODUCTION TO THE EPIGENETICS	
LANDSCAPE	75
Applications to Cancer	76
DNA Methylation	77
Covalent Histone Modifications	78
Covalent ... (Continued)	79
Covalent ... (Continued)	80
Histone Modifications in Cancer.....	81
Histone ... (Continued).....	82

microRNA.....	83
MicroRNA Technologies that Will Impact Diagnostics and Therapeutics	84
<i>TABLE 10 MIRNA AND SIRNA-A COMPARISON.....</i>	<i>85</i>
Epigenetic Changes and Cancer Stem Cells	86
Epigenetic Therapy of Cancer.....	87
Epigenetic Therapy ... (Continued).....	88
<i>TABLE 11 EPIGENETIC DRUGS APPROVED BY THE U.S. FDA.....</i>	<i>89</i>
Leading Epigenetic Companies.....	90
<i>TABLE 12 SELECTED EPIGENETIC COMPANIES</i>	<i>91</i>
Epigenetics and MicroRNA Profiling—Finding Pathways to Treatment.....	92
Currently Used MicroRNA Techniques.....	93
Currently Used ... (Continued)	94
Human Cancer and Epigenetic Regulation of miRNAs.....	95
Human Cancer ... (Continued).....	96
<i>TABLE 13 DIFFERENTIAL EXPRESSION OF MICRORNA IN CANCER.....</i>	<i>97</i>
<i>TABLE 14 EPI-MIRNAS REGULATING EFFECTORS OF THE EPIGENETIC MACHINERY</i>	<i>98</i>
MicroRNAs and Therapeutic Applications in Cancer.....	98
MicroRNAs ... (Continued).....	99
MicroRNAs ... (Continued).....	100
MicroRNAs ... (Continued).....	101
Polymorphisms in MicroRNAs Associated with Cancer Risk	102
MicroRNAs as Prognostic and Therapeutic Biomarkers	102
microRNA as Therapeutic Targets	103
Computational Methods for Analysis of Cellular Functions and Pathways.....	104
Computational ... (Continued)	105
<i>TABLE 15 LIST OF PREDICTED TARGETS THAT ARE KNOWN GENES AFFECTED IN COLON CANCER</i>	<i>106</i>
<i>TABLE 15 (CONTINUED).....</i>	<i>107</i>
Anti-Cancer Drugs and microRNA Targets	107
Anti-Cancer ... (Continued).....	108
<i>TABLE 16 LIST OF PREDICTED TARGETS THAT ARE KNOWN GENES AFFECTED IN PANCREATIC CANCER</i>	<i>109</i>
Anti-Cancer ... (Continued).....	110
Anti-Cancer ... (Continued).....	111
Anti-Cancer ... (Continued).....	112
Case Study: Epigenetic Silencing of the Intronic microRNA Mir-342 in Colorectal Cancer	113
<i>TABLE 17 MIRNAS DIFFERENTIALLY EXPRESSED BETWEEN CRC AND NORMAL COLORECTAL TISSUE.....</i>	<i>114</i>

<i>TABLE 18 MIRNAS DIFFERENTIALLY EXPRESSED BETWEEN NORMAL COLON AND EARLY STAGE COLORECTAL CANCER (STAGES I AND II)</i>	115
<i>TABLE 19 MIRNAS DIFFERENTIALLY EXPRESSED IN EARLY- (I AND II) VS LATE-STAGE (III AND IV) DISEASE</i>	116
<i>TABLE 20 PATHWAYS TARGETED BY CRC MIRNAS</i>	117
Diagnostic and Therapeutic microRNA Strategies in Cancer	118
Diagnostic and ... (Continued)	119
Diagnostic and ... (Continued)	120
<i>TABLE 21 MICRORNAS AS PROGNOSTIC INDICATORS AND THERAPEUTIC TARGETS: POTENTIAL EFFECT ON BREAST CANCER MANAGEMENT</i>	121
Therapeutic Potential.....	122
Therapeutic Potential (Continued)	123
Therapeutic Potential (Continued)	124
<i>TABLE 22 MICRORNAS (MIRS) WITH ALTERED EXPRESSION IN OVARIAN CARCINOMA</i>	125
<i>TABLE 22 (CONTINUED)</i>	126
Therapeutic Potential (Continued)	127
Therapeutic Potential (Continued)	128
Outstanding Researchers	129
Implications for Cancer	130
<i>TABLE 23 SELECTED MICRORNAS IN DEVELOPMENT AND CANCER</i>	131
MicroRNA Clinical Trials.....	132
<i>TABLE 24 ACTIVE CANCER CLINICAL TRIALS STUDYING MICRORNA PROFILING</i>	132
<i>TABLE 24 (CONTINUED)</i>	133
Ongoing Active Trials	133
Biomarkers in Tissue Samples From Patients With Stage I or Stage III Endometrial Cancer.....	133
Molecular Genetic Basis of Invasive Breast Cancer Risk Associated With Lobular Carcinoma in situ	134
Study of Specimens from Young Patients With Neuroblastoma	134
Laboratory Study of Lymphoblasts in Young Patients With High-Risk Acute Lymphoblastic Leukemia	135
The Molecular Characterization of Multiple Myeloma at Relapse	136
Molecular Analysis of Solid Tumors.....	137

A Study of Avastin (Bevacizumab) in Combination With Neoadjuvant Treatment Regimens in Patients With Primary HER2 Negative Breast Cancer Genetics Study of Tissue Collected From Patients With Acute Myeloid Leukemia	137
Genetics Study of Tissue Collected from Patients with Acute Myeloid Leukemia	138
Blood Samples from Patients with Non–Small Cell Lung Cancer and from Healthy Volunteers	138
Biological Factors Predicting Response to Chemotherapy in Advanced Non–Small Cell Lung Cancer	139
Chemotherapy and Radiation Therapy with or without Cetuximab in Treating Patients with Stage IIIA Non–Small Cell Lung Cancer	139
Azacytidine and Bortezomib in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes	139
Molecular Correlates of Sensitivity and Resistance to Therapy in Prostate Cancer	140
Study of Erlotinib with Docetaxel in Selected Non Small Cell Lung Cancer Patients in First-Line Treatment	141
Functional Pharmacogenomics of Childhood Acute Lymphoblastic Leukemia in Taiwan	142
microRNA Expression in Renal Cell Carcinoma	143
Bortezomib and Azacytidine in Treating Patients with Relapsed or Refractory T- Cell Lymphoma	143
Pharmacogenomic Study in Myeloma Patients Treated with Melphalan-Prednisone- Thalidomide or Lenalidomide- Dexamethasone	144
Study of CS-7017 in Combination with FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy	145
Integrated Whole-Genome Analysis of Hematologic Disorders	145

Unlocking Biological Processes	145
MicroRNA Patents and Outlook	146
<i>TABLE 25 MICRORNA PATENTS</i>	147
MicroRNA Patents and Outlook (Continued)	148
<i>TABLE 26 MICRORNA MARKET AND FORECAST, 2015 (\$ MILLIONS)</i>	149
<i>FIGURE 2 MICRORNA MARKET AND FORECAST, 2009-2015 (\$</i> <i>MILLIONS)</i>	149
Key miRNA Companies.....	150
Invitrogen.....	150
Illumina.....	150
Exiqon.....	150
LC Sciences	151
<i>TABLE 27 SELECTED COMPANIES FOR MIRNA-SPECIFIC TOOLS</i> <i>AND REAGENTS</i>	152
Agilent	153
SuperArray.....	153
Applied Biosystems.....	153
SABiosciences.....	153
Qiagen	154
Methylation Markers.....	154
DNA Methylation, an Epigenetic Process.....	155
Current Methods and Products	156
Current ...(continued).....	157
Current ... (Continued)	158
Cancer-specific Methylation Biomarkers.....	159
Cancer-...(Continued).....	160
Clinical Implications.....	161
Epigenetic Drugs.....	161
<i>TABLE 28 EPIGENETIC PROFILING MARKET AND FORECAST,</i> <i>THROUGH 2015 (\$ MILLIONS)</i>	162
<i>FIGURE 3 EPIGENETIC PROFILING MARKET AND FORECAST,</i> <i>2009–2015 (\$ MILLIONS)</i>	163
Epigenetic Diagnostic Development	163
<i>TABLE 29 SELECTED METHYLATION TESTS FOR CANCER</i>	164
Epigenetic Therapeutic Development.....	164
Epigenetic ... (Continued).....	165
<i>TABLE 30 EPIGENETIC DRUGS FOR CANCER-APPROVED /LATE</i> <i>STAGE CLINICAL TRIAL</i>	166
<i>TABLE 31 CLINICAL STAGE HDAC INHIBITORS</i>	167
Key Players	168
CellCentric.....	168
Epigenomics.....	168
Epizyme	169
Abbott.....	169

	Veridex	170
	OncoMethylome Sciences	170
	OncoMethylome ... (Continued)	171
TABLE 32 METHYLATION MARKERS IN DEVELOPMENT		172
	Quest Diagnostics	173
TABLE 33 SELECTED COMPANIES WITH METHYLATION PRODUCTS		174
	Orion Genomics	174
	SABiosciences	175
	Zymo Research	176
	BioChain	176
	EpigenDx	177
	Millipore.....	177
	Rubicon Genomics.....	177
	Roche NimbleGen.....	178
	SeqWright.....	178
	Qiagen	179
	EXACT Sciences Corporation	180
TABLE 34 METHYLATION MARKERS/TESTS- PATENTS		181
	Active Motif	182
	Active Motif (Continued).....	183
	Clinical Implications	184
	OncoMethylome Sciences-GST-Pi/APC Methylation Test for Detection of Prostate Cancer.....	184
	OncoMethylome ... (Continued).....	185
	Methylation Markers: Novel Ideas in Development	186
	Methylation ... (Continued).....	187
PROTEOMICS		188
PROTEOMICS AND PROTEIN PROFILING		189
Proteomics and ... (Continued)		190
TECHNIQUES		191
TABLE 35 BIOMARKERS IDENTIFIED USING TWO-DIMENSIONAL ELECTROPHORESIS (2-DE)		192
TABLE 36 BIOMARKERS IDENTIFIED USING MASS SPECTROSCOPY (MS)		193
	Techniques (Continued)	194
APPLICATIONS OF PROTEOMIC TECHNIQUES IN CANCER RESEARCH		195
TECHNOLOGIES AND LIMITATIONS		196
PROTEOMICS AND INITIATIVES		197
APPLICATIONS TO CANCER		198
	Applications to Cancer (Continued).....	199
PROTEOMICS IN THE TREATMENT OF CANCER		200
	Proteomics in the ... (Continued).....	201

CLINICAL APPLICATIONS OF PROTEOMICS	202
Clinical Applications ... (continued)	203
Clinical Applications ... (continued)	204
Clinical Applications ... (continued)	205
Clinical Applications ... (continued)	206
Clinical Applications ... (continued)	207
PROTEOMIC APPROACHES IN THERAPEUTIC TARGETS	208
Proteomic Approaches ... (Continued)	209
KEY PLAYERS.....	210
Kreatech Biotechnology.....	210
Thermo Fisher Scientific.....	210
GE Healthcare	211
ProteinOne.....	211
Waters.....	211
PerkinElmer.....	212
Protনেটেমিক্স.....	213
Whatman.....	213
Arrayit Corporation.....	214
Nutricognia	215
Qiagen	215
Luminex	216
<i>TABLE 37 ANTIBODY ARRAY VENDORS</i>	<i>216</i>
Clontech and Sigma.....	216
RayBiotch.....	217
ANALYTICAL SOFTWARE	217
Alphalyse.....	217
Protনেটেমিক্স.....	217
THERAPEUTIC AND DIAGNOSTIC COMPANIES	218
Protein Biotechnologies and BioServe.....	218
Agendia	218
Aptagen, Inc.....	218
Protein Genesis.....	219
Aurelium	219
AxCell.....	219
Celera	220
Cellzome.....	220
Cognia	220
Eprogen.....	220
Europroteome	221
Genomic Solutions	221
Glaucus Proteomics	221
Hybigenics.....	221
PROTEOMICS-BASED DIAGNOSTIC PRODUCTS	222
Matritech.....	222

MDS Proteomics	222
Myriad Genetics.....	222
NextGen Sciences	223
ProFACT Proteomics	223
Protein Pathways	223
Proteologics	224
Proteome Factory AG	224
Proteome Sciences	224
Proteome Systems	225
Proteom Tech	225
Protiveris.....	225
Quattromed.....	225
Scimagix ProteinMin	225
Sense Proteomic limited.....	226
Signature BioScience.....	226
SomaLogic	226
Structural Bioinformatics (SBI).....	226
Structural GenomiX (SGX)	226
WITA Proteomics.....	227
Xerion Pharmaceuticals	227
Zyomyx.....	227
PROTEOMICS IN INDUSTRY	227
PROTEOMIC RESEARCH CENTERS	228
Stanford University: Molecular Therapeutics Program	228
Vanderbilt University—Mass Spectrometry Research Center (MSRC).....	228
Vanderbilt University...(Continued).....	229
Vanderbilt University...(Continued).....	230
CLINICAL TRIAL USING PROTEOMICS TECHNOLOGIES FOR PERSONALIZED MEDICINE	231
PROTEOMICS AND MARKET	231
<i>TABLE 38 PROTEOMICS MARKET AND FORECAST FOR CANCER PROFILING, THROUGH 2015 (\$ MILLIONS)</i>	<i>232</i>
<i>FIGURE 4 PROTEOMICS MARKET AND FORECAST FOR CANCER PROFILING, 2009–2015 (\$ MILLIONS)</i>	<i>232</i>
GLYCOMICS.....	233
WHAT IS GLYCOMICS?	233
TECHNIQUES	234
ANALYTICAL HIGH-THROUGHPUT TECHNOLOGIES	235
EMERGENCE OF GLYCOARRAYS.....	236
GLYCOINFORMATICS.....	237
BIOMEDICAL APPLICATIONS	237
Biomedical Applications (Continued)	238

GLYCOMICS' RELATIONSHIP WITH OTHER "OMICS"	
TECHNOLOGIES	239
Glycomics for Biomarker Discovery	239
<i>TABLE 39 THE SEVEN TUMOR GLYCOME LABORATORIES</i>	239
<i>TABLE 39 (CONTINUED)</i>	240
Glycomics-biomarkers for Ovarian Cancer	240
Assessing Response to Neoadjuvant Chemotherapy with HD PET/CT, Serum Glycomic Markers and Tissue Muc-1 Isoforms.....	241
<i>TABLE 40 CLINICAL TRIALS AND GLYCOMICS</i>	242
GLYCOMICS AND PATENTS	242
Carbohydrate Encapsulated Nanoparticles	242
Glycosylated Specificity Exchangers (Tripep)	242
Glycosylated Specificity Exchangers (Tripep)	242
Tripep AB /ChronTech Pharma AB	242
<i>TABLE 41 GLYCOMICS PATENTS</i>	243
Serum Marker for Measuring Liver Fibrosis	243
COMPANIES.....	244
Glycominds Limited.....	244
Endotis Pharma.....	245
Glykoz Pty. Ltd.	245
GP Biosciences Ltd.	245
METABOLOMICS	246
WHAT IS METABOLOMICS?.....	247
METABOLOME	247
TECHNIQUES	248
Detection Methods.....	249
METABOLOMICS AND DRUG DISCOVERY	250
BIOMARKER IDENTIFICATION	251
Biomarker Identification (Continued)	252
<i>TABLE 42 ISSUED PATENTS</i>	253
CHAPTER FIVE: BIOINFORMATICS, DATABASES, AND PATHWAY	
ANALYSIS.....	254
BIOINFORMATICS, DATABASES.....	254
BIOINFORMATICS, DATABASES...(CONTINUED)	255
BIOINFORMATICS, DATABASES...(CONTINUED)	256
CHAPTER SIX: CANCER PROFILING AND CASE STUDIES	
CANCER PROFILING AND CASE STUDIES.....	257
CASE STUDIES.....	258
IN BREAST CANCER—THREE PERSPECTIVES ILLUSTRATING CURRENT CHALLENGES IN PERSONALIZED MEDICINE	258
In Breast Cancer—Three...(Continued)	259

GENE EXPRESSION PROFILING	260
Gene Expression Profiling (Continued)	261
Gene Expression Profiling (Continued)	262
Gene Expression Profiling (Continued)	263
BIOMARKERS	264
DIAGNOSTIC TESTS IN DEVELOPMENT	264
TABLE 43 <i>DIAGNOSTIC TESTS IN DEVELOPMENT</i>	265
Approved Tests	265
Approved Tests (Continued)	266
TABLE 44 <i>APPROVED DIAGNOSTIC TESTS</i>	267
Cancer and Biomarkers	268
TABLE 45 <i>KEY PREDICTIVE BIOMARKERS FOR TRASTUZUMAB</i> <i>THERAPY</i>	269
Approved Tests (Continued)	270
Approved Tests (Continued)	271
TABLE 46 <i>PREDICTIVE BIOMARKERS FOR EGFR TKI THERAPIES</i> <i>IN LUNG CANCER</i>	272
Approved Tests (Continued)	273
Approved Tests (Continued)	274
Approved Tests (Continued)	275
Approved Tests (Continued)	276
FUTURE DIRECTIONS	277
Future Directions (Continued)	278
TABLE 47 <i>PREDICTIVE BIOMARKERS FOR ANTI-EGFR ANTIBODY</i> <i>THERAPIES IN COLORECTAL CANCER</i>	279
Future Directions (Continued)	280
CHAPTER SEVEN: MARKET	281
GENOMICS MARKET	281
TRENDS	281
TABLE 48 <i>GENOMICS MARKET REVENUE AND FORECAST,</i> <i>THROUGH 2015 (\$ MILLIONS)</i>	281
FIGURE 5 <i>GENOMICS MARKET REVENUE AND FORECAST 2009–</i> <i>2015 (\$ MILLIONS)</i>	282
Genotyping and Gene Expression	282
TABLE 49 <i>GENOTYPING MARKET AND FORECAST, THROUGH 2015</i> <i>(\$ MILLIONS)</i>	283
FIGURE 6 <i>GENOTYPING MARKET AND FORECAST, 2009–2015 (\$</i> <i>MILLIONS)</i>	283
TABLE 50 <i>GENE EXPRESSION MARKET AND FORECAST,</i> <i>THROUGH 2015 (\$ MILLIONS)</i>	284
FIGURE 7 <i>GENE EXPRESSION MARKET AND FORECAST, 2009–2015</i> <i>(\$ MILLIONS)</i>	284
MICROARRAY MARKET	285
The Global Market for Microarray	285

<i>TABLE 51 GLOBAL MICROARRAY MARKET FORECAST, THROUGH 2015 (\$ MILLIONS)</i>	286
<i>FIGURE 8 GLOBAL MICROARRAY MARKET FORECAST, 2009–2015 (\$ MILLIONS)</i>	286
<i>TABLE 52 THE DIAGNOSTIC MICROARRAY MARKET AND FORECAST, THROUGH 2015 (\$ MILLIONS)</i>	287
<i>FIGURE 9 THE DIAGNOSTIC MICROARRAY MARKET AND FORECAST, 2009–2015 (\$ MILLIONS)</i>	288
The Global Market ... (Continued).....	289
<i>TABLE 53 MICROARRAY TECHNOLOGIES: COMPANIES AND PRODUCTS</i>	290
<i>TABLE 54 DNA MICROARRAY TECHNOLOGIES: COMPANIES AND REVENUE, THROUGH 2010 (\$ MILLIONS)</i>	290
<i>FIGURE 10 DNA MICROARRAY TECHNOLOGIES: COMPANIES AND REVENUE, 2008-2010 (\$ MILLIONS)</i>	291
<i>TABLE 55 AGILENT TECHNOLOGIES: ORDERS AND NET REVENUE, 2009 AND 2010 (\$ MILLIONS)</i>	291
<i>TABLE 56 DNA MICROARRAY COMPANIES' SALES AND FORECASTS, 2009 AND 2010 (\$ MILLIONS)</i>	292
<i>FIGURE 11 DNA MICROARRAY COMPANIES' SALES AND FORECAST, 2009–2010 (\$ MILLIONS)</i>	293
The Global Market ... (Continued).....	294
The Global Market ... (Continued).....	295
The Global Market ... (Continued).....	296
The Global Market ... (Continued).....	297
The Global Market ... (Continued).....	298
Sequencing and Market.....	299
<i>TABLE 57 SEQUENCING—SALES AND FORECAST, THROUGH 2015 (\$ MILLIONS)</i>	299
<i>FIGURE 12 SEQUENCING—SALES AND FORECAST, 2009–2015 (\$ MILLIONS)</i>	300
Future.....	301
Future (Continued).....	302
<i>TABLE 58 ILLUMINA—REVENUE AND FORECAST, 2008-2010 (\$ MILLIONS)</i>	303
<i>FIGURE 13 ILLUMINA—REVENUE AND FORECAST, 2008, 2009, 2010 (\$ MILLIONS)</i>	303
<i>TABLE 59 SELECTED COMPANIES AND SEQUENCING PRODUCTS</i>	304
<i>TABLE 60 LIFE TECHNOLOGIES REVENUES AND FORECAST, 2008-2010 (\$ MILLIONS)</i>	305
<i>FIGURE 14 LIFE TECHNOLOGIES REVENUES AND FORECAST, 2008-2010 (\$ MILLIONS)</i>	305
PCR Market	306

<i>TABLE 61 GLOBAL POLYMERASE CHAIN REACTION MARKET AND FORECAST THROUGH 2015 (\$ MILLIONS)</i>	<i>307</i>
<i>FIGURE 15 GLOBAL POLYMERASE CHAIN REACTION MARKET AND FORECAST, 2009–2015 (\$ MILLIONS)</i>	<i>307</i>
<i>TABLE 62 REAL-TIME (QRT-PCR) PCR SELECTED COMPANIES</i>	<i>308</i>
<i>PCR Market (Continued)</i>	<i>309</i>
<i>TABLE 63 REAL-TIME (QRT-PCR) MARKET, THROUGH 2015 (\$ MILLIONS)</i>	<i>310</i>
<i>FIGURE 16 REAL-TIME (QRT-PCR) MARKET, 2009-2015 (\$ MILLIONS)</i>	<i>310</i>
<i>EPIGENETICS AND MARKET</i>	<i>311</i>
<i>TABLE 64 GLOBAL EPIGENETIC MARKET AND FORECAST, THROUGH 2015 (\$ MILLIONS)</i>	<i>311</i>
<i>FIGURE 17 GLOBAL EPIGENETIC MARKET AND FORECAST, 2009-2015 (\$ MILLIONS)</i>	<i>312</i>
<i>TABLE 65 EPIGENETICS ARRAYS AND SELECTED CANCER PROFILING COMPANIES</i>	<i>313</i>
<i>EPIGENETIC THERAPEUTICS</i>	<i>314</i>
<i>Epigenetic Therapeutics (Continued)</i>	<i>315</i>
<i>TABLE 66 EPIGENETICS AND SELECTED COMPANIES</i>	<i>316</i>
<i>EPIGENETICS AND DIAGNOSTIC TESTS</i>	<i>317</i>
<i>TABLE 67 EPIGENETIC DIAGNOSTIC TESTS</i>	<i>317</i>
<i>MIRNA MARKET</i>	<i>317</i>
<i>miRNA Market (Continued)</i>	<i>318</i>
<i>TABLE 68 TOTAL MIRNA MARKET AND FORECAST, THROUGH 2015 (\$ MILLIONS)</i>	<i>319</i>
<i>FIGURE 18 TOTAL MIRNA MARKET AND FORECAST, 2009-2015 (\$ MILLIONS)</i>	<i>319</i>
<i>TABLE 69 TOTAL MIRNA MARKET SALES, 2008 (%)</i>	<i>320</i>
<i>EPIGENETICS AND CANCER MARKET AND FUTURE GROWTH</i>	<i>321</i>
<i>TABLE 70 SELECTED COMPANIES WITH METHYLATION PRODUCTS</i>	<i>321</i>
<i>CURRENT USE OF PROTEOMICS IN THE PHARMA INDUSTRY</i>	<i>321</i>
<i>TABLE 71 GLOBAL MARKET FOR PROTEOMICS-SALES FORECAST, THROUGH 2015 (\$ MILLIONS)</i>	<i>322</i>
<i>FIGURE 19 GLOBAL MARKET FOR PROTEOMICS-SALES FORECAST, 2009-2015 (\$ MILLIONS)</i>	<i>322</i>
<i>TABLE 72 PROTEIN-BASED MICROARRAYS MARKET AND FORECAST, THROUGH 2015 (\$ MILLIONS)</i>	<i>323</i>
<i>FIGURE 20 PROTEIN-BASED MICROARRAYS MARKET AND FORECAST, 2009-2015 (\$ MILLIONS)</i>	<i>323</i>
<i>PROTEIN MICROARRAYS AND TRENDS</i>	<i>324</i>

Protein Microarrays and ... (Continued)	325
THE METABOLOMICS MARKET	326
CONCLUSION	327
<i>TABLE 73 SELECTED COMPANIES OFFERING, DEVELOPING, OR</i>	
<i>PARTNERING TO DEVELOP COMPANION DIAGNOSTICS</i>	328
<i>TABLE 73 (CONTINUED)</i>	329
CHAPTER EIGHT: SELECTED LICENSING, COLLABORATIONS AND	
MERGERS	330
CLC BIO, ION TORRENT PARTNER ON MDX PROJECT	330
ASURAGEN IN-LICENSES BRAF MUTATION FROM JOHNS	
HOPKINS	330
GSK TO EXPLOIT SUPERGEN'S EPIGENETICS EXPERTISE IN	
CANCER COLLABORATION	331
AGENDIA AND AGILENT TECHNOLOGIES ANNOUNCE PLANS	
TO JOINTLY DEVELOP NEW DIAGNOSTIC TESTS.....	331
GENOTYPING—KAISER PERMANENTE AND THE UNIVERSITY	
OF CALIFORNIA, SAN FRANCISCO (UCSF) ENTERED INTO	
AN AGREEMENT WITH AFFYMETRIX TO CONDUCT	
GENOME-WIDE ANALYSES OF DNA SAMPLES	332
NEW GENOMIC CANCER CARE ALLIANCE FORMED TO STUDY	
WHOLE-GENOME SEQUENCING IN CANCER TREATMENT	333
CHAPTER NINE: COMPANY PROFILES	334
<i>TABLE 74 MICROARRAY COMPANIES</i>	334
<i>TABLE 74 (CONTINUED)</i>	335
OTHER KEY COMPANIES	335
MICRORNA.....	335
Asuragen	335
Regulus Therapeutics.....	335
Alnylam Pharmaceuticals	336
Isis Pharmaceuticals	336
LC Sciences	337
DNAVision	337
METHYLATION MARKERS.....	337
<i>TABLE 75 METHYLATION PRODUCTS: SELECTED COMPANIES</i>	338
<i>TABLE 76 SELECTED PROFILING COMPANIES</i>	339
CONCLUSIONS.....	339
Conclusions (Continued)	340
CHAPTER TEN: REFERENCES.....	341
REFERENCES.....	341
REFERENCES (CONTINUED)	342
REFERENCES (CONTINUED)	343